EWQ isn’t a pure French macro bet: 60% of revenue is global. At ~19x P/E, upside looks stretched; 2026 downside risks loom.
I’m excited to introduce the newest member of the Noozhawk team: Evelyn Spence, who starts Jan. 19 as our South County editor ...
Inhibrx develops next-generation protein therapeutics as nasdaq futures shape broader biotechnology discussions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback